Nicodemus; Christopher F.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Nicodemus; Christopher F..The latest application filed is for "method of indirect immunization of human ovarian cancer patients through selection of xenogeneic immunoglobulin fc portions".

Company Profile

6.10.17

Nicodemus; Christopher F. - Charlestown MA
Nicodemus; Christopher F. - Charleston MA
Nicodemus; Christopher F - Charlestown MA
Nicodemus; Christopher F. - Franconia NH

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant Grant 11,351,255 - Nicodemus , et al. June 7, 2	2022-06-07
Methods of increasing delivery of anti-cancer agents to targets Grant 10,975,163 - Madiyalakan , et al. April 13, 2	2021-04-13
Method Of Indirect Immunization Of Human Ovarian Cancer Patients Through Selection Of Xenogeneic Immunoglobulin Fc Portions App 20200206347 - Madiyalakan; Ragupathy ; et al.	2020-07-02
Treatment Of Cancer With Therapeutic Monoclonal Antibody Specific For A Tumor Associated Antigen And An Immune Adjuvant App 20200101159 - NICODEMUS; CHRISTOPHER F. ; et al.	2020-04-02
Method Of Indirect Immunization Of Human Ovarian Cancer Patients Through Selection Of Xenogeneic Immunoglobulin Fc Portions App 20200093925 - Madiyalakan; Ragupathy ; et al.	2020-03-26
Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant Grant 10,537,636 - Nicodemus , et al. Ja	2020-01-21
Tumor Antigen Specific Antibodies And Tlr3 Stimulation To Enhance The Performance Of Checkpoint Interference Therapy Of Cancer App 20190322760 - Madiyalakan; Ragupathy ; et al.	2019-10-24
Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer Grant 10,392,444 - Madiyalakan , et al. A	2019-08-27
Treatment Of Cancer With Therapeutic Monoclonal Antibody Specific For A Tumor Associated Antigen And An Immune Adjuvant App 20180221476 - NICODEMUS; Christopher F. ; et al.	2018-08-09
Treatment Of Cancer With Therapeutic Monoclonal Antibody Specific For A Tumor Associated Antigen And An Immune Adjuvant App 20180221477 - Nicodemus; Christopher F. ; et al.	2018-08-09
Methods Of Increasing Delivery Of Anti-cancer Agents To Targets App 20180002441 - Madiyalakan; Ragupathy ; et al.	2018-01-04
Methods for improving the bioactivity of therapeutic IgE antibodies for the treatment of disease Grant 8,945,566 - Schultes , et al. February 3, 2	2015-02-03
IgE antibodies for the treatment of cancer Grant 8,697,079 - Penichet , et al. April 15, 2	2014-04-15
METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASE App 20130058920 - Schultes; Birgit C. ; et al.	2013-03-07
IgE ANTIBODIES FOR THE TREATMENT OF CANCER App 20130022614 - PENICHET; MANUEL L. ; et al.	2013-01-24
METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASE App 20110256124 - Schultes; Birgit C. ; et al.	2011-10-20
Combination therapy for treating disease Grant 8,038,994 - Schultes , et al. October 18, 2	2011-10-18
IgE ANTIBODIES FOR THE TREATMENT OF CANCER App 20110091466 - PENICHET; MANUEL L. ; et al.	2011-04-21
Combination therapy for treating disease App 20080311127 - Schultes; Birgit C. ; et al.	2008-12-18
Therapeutic adjuvant App 20050271649 - Schultes, Birgit C. ; et al.	2005-12-08
Combination therapy for treating disease App 20050063976 - Schultes, Birgit C. ; et al.	2005-03-24
Therapeutic compositions that alter the immune response App 20050031619 - Nicodemus, Christopher F. ; et al.	2005-02-10
Polynucleotides that encode the human proteoglycan peptide core of the effector cells of the immune response Grant 5,171,674 - Stevens , et al. December 15, 1	1992-12-15

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.